Just read the CC notes.. little summary. not as bad imo.
-Revenue could of been much higher if not new medicaid label and inventory depletion of the old label. One analyst thinks it should be 20 percent higher. 4th Q was high order quarter and 1st Q was low. If you avg it out, it should work itself out. Like patentright1 said, if you take Q4 and Q1 revenue, we met the expectation.
-Reimbursement center (new) probably caused 5 to 7 percent on revenue. (this will slowly improve, but it hits 1st Q since it was the beginning of it.
-April is highest ever for vial shipped, but that is probably caused a bit by addition orders to fill inventory, but scrip is a record month.
-MS returned to 4th Q levels in April. (very good)
-NS grew in 1st Q, and again in April. (very good)
-RA grew in 1st Q, and again in April. (very good)
-ALS very huge potential. P2 will start soon. Orphan indication applied for.
-RA indications will be very very big and each indication has potential to be as NS or MS according to Don.
-OPEX will be $5 to $10 higher 2nd Q.
-No shareback duey little window since they report 4th Q 2/3rd into the quarter.
- Might hear some updates on 2nd Q by GS conference in June. BofA conference mid May.
I expect 2nd Q to be a record quarter. At least we didn't get bunch of warnings like 4th Q CC which bolds well in the future quarters.
I expect us to go up from here as the shorts got their win this Q. Future looks good.
I think this stock goes to 60 by year end. That being said, I sold my may calls this morning when the stock was up 3%. Still holding shares strong. I'm surprised it's higher today but I honestly had a feeling last night it would be. I think it will get manipulated back down also. May sell some covered calls. Before you all start calling me a short - i'm not. I'm long term long, but I hate losing money ;-).
Man 1st Quarter was just a quarter to get rid of all the excess fat. Low inventory, acquisition, start of new reimbursement center which lost 5 to 7 percent of revenue, no sharebuy back due to limited window, MS slowdown due to winter months, and of course the late 4th Q orders.
Here is to better 2nd Q... so far record all time best APRIL scrip and vial shipped.
It appears that management was inundated with taking on a new company, and all the transitional changes that took place. If they have the situation under control, then the future projects (trials) bode exceedingly well for the company and stockholders. Let's face it, a smallish company going through some growing pains. The Street has confidence in them and I think they can be forgiven for a blip on the way up. Our resident gurus will be doing the "math" and keep us all in the loop. In the meantime notice the lack of our resident shorties who are probably licking their soon to be considerable wounds.